Controlled release of adeno‐associated virus from alginate hydrogel microbeads with enhanced sensitivity to ultrasound

Adeno‐associated virus (AAV)‐based gene therapy holds promise as a fundamental treatment for genetic disorders. For clinical applications, it is necessary to control AAV release timing to avoid an immune response to AAV. Here we propose an ultrasound (US)‐triggered on‐demand AAV release system using...

Full description

Saved in:
Bibliographic Details
Published in:Biotechnology and bioengineering 2023-08, Vol.120 (8), p.2371-2377
Main Authors: Takatsuka, Shuhei, Kubota, Takeshi, Kurashina, Yuta, Kurihara, Sho, Hirabayashi, Motoki, Fujioka, Masato, Okano, Hirotaka James, Onoe, Hiroaki
Format: Article
Language:English
Subjects:
AAV
Acoustic impedance
Alginates
Alginic acid
Controlled release
drug release
Encapsulation
Enhancers
Gene therapy
Genetic disorders
hydrogel microbeads
Hydrogels
Immune response
Lysine
Microparticles
Microspheres
Nanoparticles
Sensitivity enhancement
Transfection
Tungsten
Ultrasound
Viruses
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adeno‐associated virus (AAV)‐based gene therapy holds promise as a fundamental treatment for genetic disorders. For clinical applications, it is necessary to control AAV release timing to avoid an immune response to AAV. Here we propose an ultrasound (US)‐triggered on‐demand AAV release system using alginate hydrogel microbeads (AHMs) with a release enhancer. By using a centrifuge‐based microdroplet shooting device, the AHMs encapsulating AAV with tungsten microparticles (W‐MPs) are fabricated. Since W‐MPs work as release enhancers, the AHMs have high sensitivity to the US with localized variation in acoustic impedance for improving the release of AAV. Furthermore, AHMs were coated with poly‐l‐lysine (PLL) to adjust the release of AAV. By applying US to the AAV encapsulating AHMs with W‐MPs, the AAV was released on demand, and gene transfection to cells by AAV was confirmed without loss of AAV activity. This proposed US‐triggered AAV release system expands methodological possibilities in gene therapy.
ISSN:0006-3592
1097-0290
DOI:10.1002/bit.28482